Pharmacy closures, medication shortages threaten access to meds: We examine some digital tools that drugmakers and pharmacies should endorse to ensure patients stay on their prescriptions.
Big 3 pharmacy benefit managers countersue FTC: They allege the FTC's case against them over insulin prices is unconstitutional. While it might be a savvy legal tactic, it shouldn’t divert attention from PBMs’ role in rising prescription drug costs.
Consumers are submitting medical scans to Elon Musk’s genAI chatbot, Grok: But Grok isn’t trained well enough on medical data, which could create a host of problems for patients.
Nearly one-quarter of working-age US adults are underinsured: More consumers are being pushed onto less generous health plans, which will inevitably result in sicker patients with higher amounts of medical debt.
Trump taps Dr. Oz to helm the CMS: We detail what the celebrity doctor’s appointment would mean for the future of Medicare, Medicaid, the Affordable Care Act, and consumers enrolled in these plans.
Dexcom, Oura partner to integrate glucose and biometric data: The tie-up should be a symbiotic one that draws customers to each company’s devices as consumers look to uncover more information about their health.
Women drive 80% of healthcare decisions, but aren’t a marketing priority: Healthcare and pharma marketers that don’t prioritize accurate portrayals of women in their ads are leaving a massive amount of money on the table.
Docs struggle to use ChatGPT for diagnosing illnesses: Chatbots have greater diagnostic accuracy by themselves than physicians using AI. We examine how doctors can get more comfortable using AI for medical diagnostics.
Pharmacy benefit managers confuse consumers and employers alike: Employers must gain a better understanding of their PBM contracts so they can steer their workers toward lower-cost drugs.
Trump taps RFK Jr. to lead Health and Human Services: If confirmed, the vaccine skeptic’s appointment would hold serious implications for Big Pharma.
FDA says Merz Pharma’s Instagram ad is misleading: The regulator could be ramping up its oversight of drug ads on social media that involve influencers.
Tech-focused primary care startup Forward shuts down: It invested too much in tech and not enough in patient care. We explore how primary care subscriptions can strike the right balance.
Amazon’s telehealth service offers upfront pricing for Prime members: This puts it in direct competition with companies like Hims & Hers and Ro. Here’s why they should be worried.
Pfizer explores a sale of its hospital drugs unit: The move was spurred by activist investor Starboard Value, which has put pressure on Pfizer to reduce its debts after taking a $1B stake in the company.
Over 80% of ad spending in the US for technology and electronics (87.1%), retail (82.9%), and consumer packaged goods (80.2%) is directed toward digital media, according to EMARKETER’s August 2024 forecast.
Half of the drugs launched in the US last year underperformed: We examine why it’s critically important for drugmakers to deliver early returns on their new product launches.
Is the retail health clinic business model dead? Our forecasts project fewer consumers will visit a retail clinic such as CVS or Walgreens every year through 2026. We detail why below.
Nutritional supplements are popular in the US, but consumers don’t know how ingredients are vetted: The situation presents brand marketers with an opportunity to fill this knowledge gap and connect with shoppers.
OpenNotes, Abridge partner to enhance AI-generated visit summaries: Providing patients with easier-to-understand summaries could reduce the time clinicians spend responding to patients.
How Trump’s victory could cut into drugmakers’ revenues: We explore how the new administration will impact prescription drug pricing, vaccine sales, and pharma advertising.